1 Biotech Goes All In
In the following video, Motley Fool health-care analyst David Williamson takes a look at NPS Pharmaceuticals' very bold move. This small company has just bought back the worldwide rights to both of its lead drugs, Gattex and Natpara, from the giant corporation Takeda. David tells investors how challenging it will be for the NPS Pharmaceuticals to take over management of worldwide sales of the two drugs, as well as just how big the potential rewards from this move could be.
While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. The Motley Fool's free report "3 Stocks That Will Help You Retire Rich" names stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.
The article 1 Biotech Goes All In originally appeared on Fool.com.David Williamson has no position in any stocks mentioned. The Motley Fool recommends BioMarin Pharmaceutical. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.